A dose-finding study of nedaplatin and cyclophosphamide for patients with gynecological malignancies

Background: Nedaplatin is a new analogue of cisplatin with similar efficacy but less renal toxicity. We investigated the appropriate dose of nedaplati n in combination with cyclophosphamide for patients with gynecological mali gnancies. Methods: Nine patients (five with ovarian cancer and four with uterine cerv ical cancer) were studied. Three patients received 60 mg/m(2) of nedaplatin combined with 500 mg/m(2) of cyclophosphamide every 4 weeks. Another three patients were each administered 80 or 100 mg/m(2) of nedaplatin with the s ame dose of cyclophosphamide. A total of 27 courses was given. Results: No patient needed dose reduction due to myelosuppression and no se vere adverse events were observed. Conclusions: Treatment with 100 mg/m(2) of nedaplatin and 500 mg/m(2) of cy clophosphamide is feasible for patients with gynecological malignancies. Ho wever, phase II studies are needed to clarify the efficacy of this combinat ion chemotherapy.